FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Portfolio Pulse from
The FDA has approved Genentech's Evrysdi tablet, the first and only tablet for treating spinal muscular atrophy (SMA). This approval marks a significant advancement as Evrysdi is the only non-invasive disease-modifying treatment for SMA.
February 12, 2025 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genentech, part of the Roche Group, received FDA approval for its Evrysdi tablet, the first non-invasive treatment for SMA. This approval could enhance Genentech's market position in SMA treatments.
The FDA approval of Evrysdi as the first non-invasive tablet for SMA is a significant milestone for Genentech, potentially boosting its market share and revenue in the SMA treatment space. This approval is likely to positively impact RHHBY's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90